Peng, Ren-Wang

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 129

Differential effect of exocytic SNAREs on the production of recombinant proteins in mammalian cells

Peng, R., Abellan, E., & Fussenegger, M. (2011) · Biotechnology and Bioengineering

Cellular transport and secretionViral Infectious Diseases and Gene Expression in Insects

Cited by 61

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer

Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis

Lung Cancer Treatments and MutationsEndoplasmic Reticulum Stress and Disease

Cited by 58

mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer

Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene

PI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

Cited by 55

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit

Ning, W., Marti, T. M., Dorn, P., & Peng, R.-W. (2022) · Frontiers in Oncology

Cancer Cells and MetastasisLung Cancer Treatments and Mutations

Cited by 29